BACKGROUND AND OBJECTIVE:Metformin is an effective treatment for type 2 diabetes mellitus. The pharmacokinetic characteristics of the conventional immediate-release (IR) formulation of metformin (Glucophage), however, necessitate two- or three-times-daily dosing. Development of a novel extended-release (XR) formulation of metformin (Glucophage XR) using GelShield Diffusion System technology provides a once-daily dosing option. The objective of this study was to assess the steady-state pharmacokinetics of metformin XR tablets. STUDY DESIGN: This was an open-label, multiple-dose, five-regimen, two-sequence clinical study lasting 5 weeks. METHODS:Subjects were 16 healthy volunteers aged 18-40 years. Three 1-week regimens of metformin XR (500, 1000 and 1500 mg once daily) were administered sequentially. Subjects were alternately given either metformin XR 2000 mg once daily or metformin IR 1000 mg twice daily during weeks 4 and 5. The pharmacokinetic properties of metformin XR were assessed on two separate days at steady state and compared with those of metformin IR. RESULTS:Absorption of metformin XR was slower than that of metformin IR (time to maximum plasma concentration = 7 versus 3 hours). Maximum plasma concentrations (Cmax) following the administration of metformin XR 2000 mg once daily was 36% higher than that following the evening dose of metformin IR 1000 mg twice daily. The extent of absorption, determined by area under the plasma concentration-time curve (AUC), was equivalent for both formulations. The mean accumulation ratio of metformin XR was 1.0, indicating no accumulation with multiple-dose administration. Intrasubject variabilities in Cmax and AUC of metformin were comparable between metformin XR and metformin IR. This novel formulation of metformin XR was well tolerated at single doses up to 2000 mg once daily for 7 days, and adverse events were similar to those reported with metformin IR. CONCLUSION: The pharmacokinetic parameters of metformin XR tablet using GelShield Diffusion System technology were similar to those of metformin IR. Metformin XR was well tolerated at single doses up to 2000 mg once daily.
RCT Entities:
BACKGROUND AND OBJECTIVE:Metformin is an effective treatment for type 2 diabetes mellitus. The pharmacokinetic characteristics of the conventional immediate-release (IR) formulation of metformin (Glucophage), however, necessitate two- or three-times-daily dosing. Development of a novel extended-release (XR) formulation of metformin (Glucophage XR) using GelShield Diffusion System technology provides a once-daily dosing option. The objective of this study was to assess the steady-state pharmacokinetics of metformin XR tablets. STUDY DESIGN: This was an open-label, multiple-dose, five-regimen, two-sequence clinical study lasting 5 weeks. METHODS: Subjects were 16 healthy volunteers aged 18-40 years. Three 1-week regimens of metformin XR (500, 1000 and 1500 mg once daily) were administered sequentially. Subjects were alternately given either metformin XR 2000 mg once daily or metformin IR 1000 mg twice daily during weeks 4 and 5. The pharmacokinetic properties of metformin XR were assessed on two separate days at steady state and compared with those of metformin IR. RESULTS: Absorption of metformin XR was slower than that of metformin IR (time to maximum plasma concentration = 7 versus 3 hours). Maximum plasma concentrations (Cmax) following the administration of metformin XR 2000 mg once daily was 36% higher than that following the evening dose of metformin IR 1000 mg twice daily. The extent of absorption, determined by area under the plasma concentration-time curve (AUC), was equivalent for both formulations. The mean accumulation ratio of metformin XR was 1.0, indicating no accumulation with multiple-dose administration. Intrasubject variabilities in Cmax and AUC of metformin were comparable between metformin XR and metformin IR. This novel formulation of metformin XR was well tolerated at single doses up to 2000 mg once daily for 7 days, and adverse events were similar to those reported with metformin IR. CONCLUSION: The pharmacokinetic parameters of metformin XR tablet using GelShield Diffusion System technology were similar to those of metformin IR. Metformin XR was well tolerated at single doses up to 2000 mg once daily.
Authors: J M Hebden; P J Gilchrist; E Blackshaw; M E Frier; A C Perkins; C G Wilson; R C Spiller Journal: Eur J Gastroenterol Hepatol Date: 1999-12 Impact factor: 2.566
Authors: N C Sambol; J Chiang; M O'Conner; C Y Liu; E T Lin; A M Goodman; L Z Benet; J H Karam Journal: J Clin Pharmacol Date: 1996-11 Impact factor: 3.126
Authors: Janna K Duong; M Y A M Kroonen; S S Kumar; H L Heerspink; C M Kirkpatrick; G G Graham; K M Williams; R O Day Journal: Eur J Clin Pharmacol Date: 2017-04-28 Impact factor: 2.953
Authors: Anders Gummesson; Haiyan Li; Michael Gillen; John Xu; Mohammad Niazi; Boaz Hirshberg Journal: Clin Drug Investig Date: 2014-11 Impact factor: 2.859
Authors: Elise J Smolders; Angela Colbers; Clara T M M de Kanter; Kirsten Velthoven-Graafland; Leonie T Wolberink; Noor van Ewijk-Beneken Kolmer; Joost P H Drenth; Rob E Aarnoutse; Cees J Tack; David M Burger Journal: Br J Clin Pharmacol Date: 2017-06-06 Impact factor: 4.335
Authors: Janna K Duong; Shaun S Kumar; Carl M Kirkpatrick; Louise C Greenup; Manit Arora; Toong C Lee; Peter Timmins; Garry G Graham; Timothy J Furlong; Jerry R Greenfield; Kenneth M Williams; Richard O Day Journal: Clin Pharmacokinet Date: 2013-05 Impact factor: 6.447
Authors: S L Stocker; K M Morrissey; S W Yee; R A Castro; L Xu; A Dahlin; A H Ramirez; D M Roden; R A Wilke; C A McCarty; R L Davis; C M Brett; K M Giacomini Journal: Clin Pharmacol Ther Date: 2012-10-17 Impact factor: 6.875